Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Inclusion Criteria:
Exclusion Criteria:
Troy, Michigan 48098, United States
Winston-Salem, North Carolina 27157, United States
Ciudad Autonoma de Buenos Aire, Buenos Aires C1405BUB, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Aires 1056, Argentina
CABA, Ciudad Autónoma de Buenos Aire C1061AAS, Argentina
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
Yamato-shi, Kanagawa 242-0004, Japan
Suita-shi, Osaka 565-0853, Japan
Ootaku, Tokyo 143-0015, Japan
Changhua County, Changhua 50006, Taiwan